U.S. companies across sectors such as food and beverage makers and manufacturers of glucose monitors are facing investor questions over the risk to future sales from the growing popularity of promising weight-loss treatments. Drugs in a class known as GLP-1 such as Novo Nordisk's Wegovy and Ozempic as well as Eli Lilly's Mounjaro and Zepbound have been shown to help control blood sugar and dramatically lower weight in clinical trials.
Novo Nordisk on Saturday presented data showing that the heart protective benefits of Wegovy are not solely due to weight loss. Here's what companies have said about the potential impact: RETAILERS, FOOD & BEVERAGE Conagra might consider changing portion sizes of its snacks if the rising use of weight-loss drugs leads to a change in food consumption patterns. Walmart expects revenues from its health and wellness products to increase in the second half of the year, mainly due to the popularity of weight-loss drug
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CBSNews - 🏆 87. / 68 Read more »
Source: TheBlock__ - 🏆 464. / 53 Read more »
Source: InsideEVs - 🏆 579. / 51 Read more »
Source: InsideEVs - 🏆 579. / 51 Read more »
Source: nbcsandiego - 🏆 524. / 51 Read more »